Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-12-15

AUTHORS

Yong Wha Moon, Joo Hyuk Sohn, Hye Jin Choi, Hyun Chang, Byeong-Woo Park, Seung Il Kim, Seho Park, Ja Seung Koo, Yong Tai Kim, Jae Kyung Roh, Hyun Cheol Chung, Joo-Hang Kim

ABSTRACT

BackgroundWe evaluated the efficacy and tolerability of combined paclitaxel and ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer (MBC).MethodsPatients received paclitaxel (175 mg/m2 i.v. in a 3-h infusion) on day 1 and ifosfamide (1.5 g/m2 i.v. in a 15-min infusion) on days 1–3, every 3 weeks for a maximum of nine cycles. The tumor response was assessed every two cycles.ResultsWe enrolled 34 patients with a median age of 50 years. Thirty patients had visceral metastases. Anthracycline- and docetaxel-based chemotherapy had previously been administered to 18/13 and 13/21 patients, respectively, in (neo)adjuvant/metastatic settings. Three patients had not previously received anthracycline due to abnormal cardiac functions. A total of 174 cycles of chemotherapy were delivered with a median of six cycles. The response rate under the intent-to-treat analysis was 23.5% (all partial responses) with a median response duration of 14 months. The disease control rate was 70.6%. The median progression-free and overall survival were 5.9 and 8.5 months, respectively. There was no apparent relationship between activity and prior docetaxel resistance. The incidence of grade III/IV neutropenia was 46.6% (81 of 174 cycles) with febrile neutropenia of only 1.7%. Major grade III/IV non-hematological toxicities included peripheral neuropathy (6 of 34 patients) and infection (4 of 34 patients). There were no treatment-related deaths.ConclusionPaclitaxel combined with ifosfamide was effective and tolerable in anthracycline-/docetaxel-pretreated MBC. Overcoming docetaxel resistance by using paclitaxel in combination with ifosfamide needs to be addressed through further investigation. More... »

PAGES

425-431

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-009-1176-5

DOI

http://dx.doi.org/10.1007/s00280-009-1176-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1018064190

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20012956


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anthracyclines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Docetaxel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ifosfamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neutropenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Paclitaxel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Taxoids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moon", 
        "givenName": "Yong Wha", 
        "id": "sg:person.0706167144.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706167144.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sohn", 
        "givenName": "Joo Hyuk", 
        "id": "sg:person.0661267733.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0661267733.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Choi", 
        "givenName": "Hye Jin", 
        "id": "sg:person.01363365111.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363365111.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chang", 
        "givenName": "Hyun", 
        "id": "sg:person.01050766347.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050766347.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Yonsei University College of Medicine, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Surgery, Yonsei University College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Park", 
        "givenName": "Byeong-Woo", 
        "id": "sg:person.01362302775.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362302775.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Yonsei University College of Medicine, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Surgery, Yonsei University College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Seung Il", 
        "id": "sg:person.01005073521.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005073521.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Yonsei University College of Medicine, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Surgery, Yonsei University College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Park", 
        "givenName": "Seho", 
        "id": "sg:person.01053206721.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053206721.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, Yonsei University College of Medicine, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Pathology, Yonsei University College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Koo", 
        "givenName": "Ja Seung", 
        "id": "sg:person.014011350677.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014011350677.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hemato-Oncology, National Health Insurance Corporation Ilsan Hospital, Goyang, Gyeonggi-do, Korea", 
          "id": "http://www.grid.ac/institutes/grid.416665.6", 
          "name": [
            "Division of Hemato-Oncology, National Health Insurance Corporation Ilsan Hospital, Goyang, Gyeonggi-do, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Yong Tai", 
        "id": "sg:person.01035015617.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035015617.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roh", 
        "givenName": "Jae Kyung", 
        "id": "sg:person.0767622633.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767622633.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chung", 
        "givenName": "Hyun Cheol", 
        "id": "sg:person.016554426212.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016554426212.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Joo-Hang", 
        "id": "sg:person.012631625664.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012631625664.47"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1023/a:1005882314735", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036855429", 
          "https://doi.org/10.1023/a:1005882314735"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-004-2184-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024820292", 
          "https://doi.org/10.1007/s10549-004-2184-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-007-9651-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039908752", 
          "https://doi.org/10.1007/s10549-007-9651-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-12-15", 
    "datePublishedReg": "2009-12-15", 
    "description": "BackgroundWe evaluated the efficacy and tolerability of combined paclitaxel and ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer (MBC).MethodsPatients received paclitaxel (175\u00a0mg/m2 i.v. in a 3-h infusion) on day 1 and ifosfamide (1.5\u00a0g/m2 i.v. in a 15-min infusion) on days 1\u20133, every 3\u00a0weeks for a maximum of nine cycles. The tumor response was assessed every two cycles.ResultsWe enrolled 34 patients with a median age of 50\u00a0years. Thirty patients had visceral metastases. Anthracycline- and docetaxel-based chemotherapy had previously been administered to 18/13 and 13/21 patients, respectively, in (neo)adjuvant/metastatic settings. Three patients had not previously received anthracycline due to abnormal cardiac functions. A total of 174 cycles of chemotherapy were delivered with a median of six cycles. The response rate under the intent-to-treat analysis was 23.5% (all partial responses) with a median response duration of 14\u00a0months. The disease control rate was 70.6%. The median progression-free and overall survival were 5.9 and 8.5\u00a0months, respectively. There was no apparent relationship between activity and prior docetaxel resistance. The incidence of grade III/IV neutropenia was 46.6% (81 of 174 cycles) with febrile neutropenia of only 1.7%. Major grade III/IV non-hematological toxicities included peripheral neuropathy (6 of 34 patients) and infection (4 of 34 patients). There were no treatment-related deaths.ConclusionPaclitaxel combined with ifosfamide was effective and tolerable in anthracycline-/docetaxel-pretreated MBC. Overcoming docetaxel resistance by using paclitaxel in combination with ifosfamide needs to be addressed through further investigation.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00280-009-1176-5", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "66"
      }
    ], 
    "keywords": [
      "metastatic breast cancer", 
      "docetaxel resistance", 
      "breast cancer", 
      "day 1", 
      "grade III/IV neutropenia", 
      "cycles of chemotherapy", 
      "median response duration", 
      "disease control rate", 
      "non-hematological toxicities", 
      "treatment-related deaths", 
      "docetaxel-based chemotherapy", 
      "abnormal cardiac function", 
      "combined paclitaxel", 
      "visceral metastases", 
      "metastatic setting", 
      "febrile neutropenia", 
      "median age", 
      "treat analysis", 
      "overall survival", 
      "tumor response", 
      "control rate", 
      "cardiac function", 
      "response duration", 
      "response rate", 
      "patients", 
      "anthracyclines", 
      "paclitaxel", 
      "neutropenia", 
      "chemotherapy", 
      "ifosfamide", 
      "cancer", 
      "further investigation", 
      "months", 
      "activity independence", 
      "apparent relationship", 
      "MethodsPatients", 
      "tolerability", 
      "BackgroundWe", 
      "metastasis", 
      "infection", 
      "incidence", 
      "weeks", 
      "ResultsWe", 
      "median", 
      "efficacy", 
      "death", 
      "survival", 
      "age", 
      "total", 
      "resistance", 
      "toxicity", 
      "duration", 
      "rate", 
      "years", 
      "setting", 
      "response", 
      "activity", 
      "peripherals", 
      "intent", 
      "cycle", 
      "need", 
      "combination", 
      "function", 
      "relationship", 
      "investigation", 
      "analysis", 
      "independence", 
      "maximum"
    ], 
    "name": "Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance", 
    "pagination": "425-431", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1018064190"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-009-1176-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20012956"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-009-1176-5", 
      "https://app.dimensions.ai/details/publication/pub.1018064190"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_476.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00280-009-1176-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-009-1176-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-009-1176-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-009-1176-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-009-1176-5'


 

This table displays all metadata directly associated to this object as RDF triples.

298 TRIPLES      22 PREDICATES      115 URIs      104 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-009-1176-5 schema:about N2e50d8055710408b977fc9a18aeb2e31
2 N310f006ed2804254be2a823f9b486dfb
3 N3c52540ae8904c60a4e40e7e104fb1e9
4 N3cf523df8ce94ab2bf4fe13e9f292318
5 N412fa24646e74ccdb7a06a94bc77e0c1
6 N44847e4c94b44cf18cda8549fa0fdc81
7 N4816542bedb24b8abb7a866987375ee6
8 N6a2f05a5a3524e3fb651d202c7f40bf7
9 Nacff3052ff274f2090682628f439b56b
10 Nb08666d3d8b84750b41a0b397a50c86d
11 Nbe65652336b0493b98a58db3351f2471
12 Nc4c5bfbab6cf48d99765e0bd15dfdbe3
13 Nc78685e5e77f4b49a6c3e0c8ad41cecc
14 Ncc7e3470ee1847bfa2fbe6087653814e
15 Nd2fe4454de7f4196884770f0da707acd
16 Ne3030235971b451e84b1f20439af181d
17 Ne56cc9978c8248c696a3216d51863d2a
18 Nfde4598fdaa74b9b88e0a77b3d3ad44d
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author N97849fe78c8a4f1c9d22ae1d28524fdf
22 schema:citation sg:pub.10.1007/s10549-004-2184-0
23 sg:pub.10.1007/s10549-007-9651-3
24 sg:pub.10.1023/a:1005882314735
25 schema:datePublished 2009-12-15
26 schema:datePublishedReg 2009-12-15
27 schema:description BackgroundWe evaluated the efficacy and tolerability of combined paclitaxel and ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer (MBC).MethodsPatients received paclitaxel (175 mg/m2 i.v. in a 3-h infusion) on day 1 and ifosfamide (1.5 g/m2 i.v. in a 15-min infusion) on days 1–3, every 3 weeks for a maximum of nine cycles. The tumor response was assessed every two cycles.ResultsWe enrolled 34 patients with a median age of 50 years. Thirty patients had visceral metastases. Anthracycline- and docetaxel-based chemotherapy had previously been administered to 18/13 and 13/21 patients, respectively, in (neo)adjuvant/metastatic settings. Three patients had not previously received anthracycline due to abnormal cardiac functions. A total of 174 cycles of chemotherapy were delivered with a median of six cycles. The response rate under the intent-to-treat analysis was 23.5% (all partial responses) with a median response duration of 14 months. The disease control rate was 70.6%. The median progression-free and overall survival were 5.9 and 8.5 months, respectively. There was no apparent relationship between activity and prior docetaxel resistance. The incidence of grade III/IV neutropenia was 46.6% (81 of 174 cycles) with febrile neutropenia of only 1.7%. Major grade III/IV non-hematological toxicities included peripheral neuropathy (6 of 34 patients) and infection (4 of 34 patients). There were no treatment-related deaths.ConclusionPaclitaxel combined with ifosfamide was effective and tolerable in anthracycline-/docetaxel-pretreated MBC. Overcoming docetaxel resistance by using paclitaxel in combination with ifosfamide needs to be addressed through further investigation.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree false
31 schema:isPartOf N1793958109614ba584bec96a53c21cf3
32 N9c195e0367fc4b1e9390545140055533
33 sg:journal.1088364
34 schema:keywords BackgroundWe
35 MethodsPatients
36 ResultsWe
37 abnormal cardiac function
38 activity
39 activity independence
40 age
41 analysis
42 anthracyclines
43 apparent relationship
44 breast cancer
45 cancer
46 cardiac function
47 chemotherapy
48 combination
49 combined paclitaxel
50 control rate
51 cycle
52 cycles of chemotherapy
53 day 1
54 death
55 disease control rate
56 docetaxel resistance
57 docetaxel-based chemotherapy
58 duration
59 efficacy
60 febrile neutropenia
61 function
62 further investigation
63 grade III/IV neutropenia
64 ifosfamide
65 incidence
66 independence
67 infection
68 intent
69 investigation
70 maximum
71 median
72 median age
73 median response duration
74 metastasis
75 metastatic breast cancer
76 metastatic setting
77 months
78 need
79 neutropenia
80 non-hematological toxicities
81 overall survival
82 paclitaxel
83 patients
84 peripherals
85 rate
86 relationship
87 resistance
88 response
89 response duration
90 response rate
91 setting
92 survival
93 tolerability
94 total
95 toxicity
96 treat analysis
97 treatment-related deaths
98 tumor response
99 visceral metastases
100 weeks
101 years
102 schema:name Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance
103 schema:pagination 425-431
104 schema:productId N4f66be9af2484974989d759be0f0857f
105 Na3436e0b64f24ddcbf68dc62e10998cc
106 Ne0b824d35b854fec879e57a27bfca8be
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018064190
108 https://doi.org/10.1007/s00280-009-1176-5
109 schema:sdDatePublished 2022-05-20T07:25
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher N661581a4df1e454ab47562613db98a5e
112 schema:url https://doi.org/10.1007/s00280-009-1176-5
113 sgo:license sg:explorer/license/
114 sgo:sdDataset articles
115 rdf:type schema:ScholarlyArticle
116 N1329de12f9c944709b702b2084a4f4d6 rdf:first sg:person.01050766347.58
117 rdf:rest N1eb8ad06387949f69bf37f53f6232b99
118 N1793958109614ba584bec96a53c21cf3 schema:issueNumber 3
119 rdf:type schema:PublicationIssue
120 N1eb8ad06387949f69bf37f53f6232b99 rdf:first sg:person.01362302775.25
121 rdf:rest Nb9eba6dd3af24483bbd54d2c2e9c9fb1
122 N2e50d8055710408b977fc9a18aeb2e31 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Adult
124 rdf:type schema:DefinedTerm
125 N310f006ed2804254be2a823f9b486dfb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Treatment Outcome
127 rdf:type schema:DefinedTerm
128 N36e359cf7ee64782bd0975344cc44063 rdf:first sg:person.012631625664.47
129 rdf:rest rdf:nil
130 N3c52540ae8904c60a4e40e7e104fb1e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Neoplasm Metastasis
132 rdf:type schema:DefinedTerm
133 N3cf523df8ce94ab2bf4fe13e9f292318 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Antineoplastic Combined Chemotherapy Protocols
135 rdf:type schema:DefinedTerm
136 N3d9a5d4d6d0a4bf7961bc5ed51eba349 rdf:first sg:person.0767622633.82
137 rdf:rest Nd3dee3676d3e4d5ea443fd99bcf31265
138 N412fa24646e74ccdb7a06a94bc77e0c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Middle Aged
140 rdf:type schema:DefinedTerm
141 N44847e4c94b44cf18cda8549fa0fdc81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Ifosfamide
143 rdf:type schema:DefinedTerm
144 N4816542bedb24b8abb7a866987375ee6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Survival Rate
146 rdf:type schema:DefinedTerm
147 N4a235219614a4cfaaa760cb17019b062 rdf:first sg:person.0661267733.85
148 rdf:rest N9682ceddce6c462c8e2cbb313ef192fb
149 N4f66be9af2484974989d759be0f0857f schema:name dimensions_id
150 schema:value pub.1018064190
151 rdf:type schema:PropertyValue
152 N524664c9245049eb83936c46c893f2bc rdf:first sg:person.01053206721.15
153 rdf:rest Nd8f407d588aa410d958252971eaba710
154 N661581a4df1e454ab47562613db98a5e schema:name Springer Nature - SN SciGraph project
155 rdf:type schema:Organization
156 N6a2f05a5a3524e3fb651d202c7f40bf7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Female
158 rdf:type schema:DefinedTerm
159 N9682ceddce6c462c8e2cbb313ef192fb rdf:first sg:person.01363365111.85
160 rdf:rest N1329de12f9c944709b702b2084a4f4d6
161 N97849fe78c8a4f1c9d22ae1d28524fdf rdf:first sg:person.0706167144.03
162 rdf:rest N4a235219614a4cfaaa760cb17019b062
163 N9c195e0367fc4b1e9390545140055533 schema:volumeNumber 66
164 rdf:type schema:PublicationVolume
165 Na3436e0b64f24ddcbf68dc62e10998cc schema:name pubmed_id
166 schema:value 20012956
167 rdf:type schema:PropertyValue
168 Nacff3052ff274f2090682628f439b56b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Breast Neoplasms
170 rdf:type schema:DefinedTerm
171 Nb08666d3d8b84750b41a0b397a50c86d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Anthracyclines
173 rdf:type schema:DefinedTerm
174 Nb9eba6dd3af24483bbd54d2c2e9c9fb1 rdf:first sg:person.01005073521.69
175 rdf:rest N524664c9245049eb83936c46c893f2bc
176 Nbe65652336b0493b98a58db3351f2471 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Paclitaxel
178 rdf:type schema:DefinedTerm
179 Nc20bebd208f241a789576116c2c54cc0 rdf:first sg:person.01035015617.86
180 rdf:rest N3d9a5d4d6d0a4bf7961bc5ed51eba349
181 Nc4c5bfbab6cf48d99765e0bd15dfdbe3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Docetaxel
183 rdf:type schema:DefinedTerm
184 Nc78685e5e77f4b49a6c3e0c8ad41cecc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Humans
186 rdf:type schema:DefinedTerm
187 Ncc7e3470ee1847bfa2fbe6087653814e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Retrospective Studies
189 rdf:type schema:DefinedTerm
190 Nd2fe4454de7f4196884770f0da707acd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Drug Resistance, Neoplasm
192 rdf:type schema:DefinedTerm
193 Nd3dee3676d3e4d5ea443fd99bcf31265 rdf:first sg:person.016554426212.74
194 rdf:rest N36e359cf7ee64782bd0975344cc44063
195 Nd8f407d588aa410d958252971eaba710 rdf:first sg:person.014011350677.08
196 rdf:rest Nc20bebd208f241a789576116c2c54cc0
197 Ne0b824d35b854fec879e57a27bfca8be schema:name doi
198 schema:value 10.1007/s00280-009-1176-5
199 rdf:type schema:PropertyValue
200 Ne3030235971b451e84b1f20439af181d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Taxoids
202 rdf:type schema:DefinedTerm
203 Ne56cc9978c8248c696a3216d51863d2a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Aged
205 rdf:type schema:DefinedTerm
206 Nfde4598fdaa74b9b88e0a77b3d3ad44d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Neutropenia
208 rdf:type schema:DefinedTerm
209 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
210 schema:name Medical and Health Sciences
211 rdf:type schema:DefinedTerm
212 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
213 schema:name Oncology and Carcinogenesis
214 rdf:type schema:DefinedTerm
215 sg:journal.1088364 schema:issn 0344-5704
216 1432-0843
217 schema:name Cancer Chemotherapy and Pharmacology
218 schema:publisher Springer Nature
219 rdf:type schema:Periodical
220 sg:person.01005073521.69 schema:affiliation grid-institutes:grid.15444.30
221 schema:familyName Kim
222 schema:givenName Seung Il
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005073521.69
224 rdf:type schema:Person
225 sg:person.01035015617.86 schema:affiliation grid-institutes:grid.416665.6
226 schema:familyName Kim
227 schema:givenName Yong Tai
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035015617.86
229 rdf:type schema:Person
230 sg:person.01050766347.58 schema:affiliation grid-institutes:grid.15444.30
231 schema:familyName Chang
232 schema:givenName Hyun
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050766347.58
234 rdf:type schema:Person
235 sg:person.01053206721.15 schema:affiliation grid-institutes:grid.15444.30
236 schema:familyName Park
237 schema:givenName Seho
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053206721.15
239 rdf:type schema:Person
240 sg:person.012631625664.47 schema:affiliation grid-institutes:grid.15444.30
241 schema:familyName Kim
242 schema:givenName Joo-Hang
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012631625664.47
244 rdf:type schema:Person
245 sg:person.01362302775.25 schema:affiliation grid-institutes:grid.15444.30
246 schema:familyName Park
247 schema:givenName Byeong-Woo
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362302775.25
249 rdf:type schema:Person
250 sg:person.01363365111.85 schema:affiliation grid-institutes:grid.15444.30
251 schema:familyName Choi
252 schema:givenName Hye Jin
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363365111.85
254 rdf:type schema:Person
255 sg:person.014011350677.08 schema:affiliation grid-institutes:grid.15444.30
256 schema:familyName Koo
257 schema:givenName Ja Seung
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014011350677.08
259 rdf:type schema:Person
260 sg:person.016554426212.74 schema:affiliation grid-institutes:grid.15444.30
261 schema:familyName Chung
262 schema:givenName Hyun Cheol
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016554426212.74
264 rdf:type schema:Person
265 sg:person.0661267733.85 schema:affiliation grid-institutes:grid.15444.30
266 schema:familyName Sohn
267 schema:givenName Joo Hyuk
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0661267733.85
269 rdf:type schema:Person
270 sg:person.0706167144.03 schema:affiliation grid-institutes:grid.15444.30
271 schema:familyName Moon
272 schema:givenName Yong Wha
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706167144.03
274 rdf:type schema:Person
275 sg:person.0767622633.82 schema:affiliation grid-institutes:grid.15444.30
276 schema:familyName Roh
277 schema:givenName Jae Kyung
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767622633.82
279 rdf:type schema:Person
280 sg:pub.10.1007/s10549-004-2184-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024820292
281 https://doi.org/10.1007/s10549-004-2184-0
282 rdf:type schema:CreativeWork
283 sg:pub.10.1007/s10549-007-9651-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039908752
284 https://doi.org/10.1007/s10549-007-9651-3
285 rdf:type schema:CreativeWork
286 sg:pub.10.1023/a:1005882314735 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036855429
287 https://doi.org/10.1023/a:1005882314735
288 rdf:type schema:CreativeWork
289 grid-institutes:grid.15444.30 schema:alternateName Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, Korea
290 Department of Pathology, Yonsei University College of Medicine, Seoul, Korea
291 Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
292 schema:name Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, Korea
293 Department of Pathology, Yonsei University College of Medicine, Seoul, Korea
294 Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
295 rdf:type schema:Organization
296 grid-institutes:grid.416665.6 schema:alternateName Division of Hemato-Oncology, National Health Insurance Corporation Ilsan Hospital, Goyang, Gyeonggi-do, Korea
297 schema:name Division of Hemato-Oncology, National Health Insurance Corporation Ilsan Hospital, Goyang, Gyeonggi-do, Korea
298 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...